Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and drug delivery of peptides for therapeutic use in the United States. Its patented oral and nasal drug delivery technologies deliver therapeutically useful amounts of various peptides into the bloodstream. The company offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. It is also developing oral calcitonin that has completed a Phase III testing for the treatment of osteoporosis. In addition, the company is also developing a pre-clinical anorexigenic peptide, UGP281 for obesity. It has license agreements with Tarsa Therapeutics, Inc. and Novartis Pharma AG for the development of oral calcitonin program. Unigene Laboratories, Inc. was founded in 1980 and is headquartered in Boonton, New Jersey. On July 2, 2013, Unigene Laboratories Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.